Anavex Life Sciences Corp (AVXL)

[falconer66a]

New Anavex Clinical Studies.

Anavex webpage text:
[insert-text-here]

Current Job Openings

Director/Senior Director, Biostatistics
Senior/Exective [sic] Director, Clinical Development & Medical Evidence
Director/Senior Director/Executive Director, Clinical Development

I clicked on each of these to see what they might reveal. My impressions:

1. Director/Senior Director, Biostatistics

“This position will have full responsibility for the methodological and statistical considerations in the design, implementation and conduct of clinical studies as part of the development program team.”

Very clear; Anavex intends to implement and conduct new clinical studies. New Anavex clinical studies to happen; beyond those currently in operation. Someone with a PhD in biostatistics needed to properly quantify new clinical data.

2. Senior/Executive Director, Clinical Development and Medical Evidence

“This position will have full responsibility for contributing epidemiologic expertise in the planning, design, implementation and analysis of drug development projects and evidence generation across the clinical development span.”

Clear, again. New clinical programs by Anavex; beyond those presently in operation.

3. Director/Senior Director/Executive Director, Clinical Development

“This position will have full responsibility for planning, implementation and daily operation of drug development projects.”

This person will direct and oversee all of the above.

Big things being planned for. Existing managers not up to the new tasks; new executives are needed.

Think not? Click on the URL at the top and read the details of each of these positions. I’ve mentioned just an opening summary sentence. A multitude of details are listed on each page.

So, is CEO Christopher Missling passing his time twiddling his thumbs; or is he and his team planning to run new clinical trials with the Anavex molecules, for additional pathologies? If so, are these new trials wide shots in the dark, seeing if anything happens? Or, does Missling have a lot of proprietary information that supports greatly expanded clinical trials, for new diseases and conditions? Ever since Missling made his tangential remark about the “Anavex iceberg,” lo those many months and years ago, I’ve always presumed that Anavex has copious amounts of pre-clinical data that indicate both safety and efficacy for a diversity of diseases and conditions.

Now, it’ll all come into play. Continuing new announcements in coming months and years. Sigma-1 receptor biology, modulated and facilitated by Anavex’s proprietary molecules, yielding safe, new therapeutic outcomes will be front-page news in 2022 and 2023; building upon the positive outcomes of the Parkinson’s disease dementia, Rett syndrome, and Alzheimer’s studies. Plan for it. Anavex obviously is.